XML 98 R26.htm IDEA: XBRL DOCUMENT
v3.25.2

SEGMENT INFORMATION (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Schedule of segment reporting information |
Schedule of segment reporting information |  |  |  |  |  |  |  |
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |
Total revenues(b) |  | $ | 168,721 |  |  | $ | 110,748 |
Less: |  |  |  |  |  |  |  |
Cost of revenues |  |  | 36,593 |  |  |  | 25,688 |
Research and development expense (excluding stock-based compensation expense): |  |  |  |  |  |  |  |
Clinical trials |  |  | 87,492 |  |  |  | 80,569 |
HALO Design |  |  | 534,527 |  |  |  | 336,870 |
SYNC project |  |  | 102,565 |  |  |  | - |
Other research and development(a) |  |  | 66,300 |  |  |  | 4,372 |
General and administrative expense (excluding share-based compensation expense) |  |  | 2,553,459 |  |  |  | 2,367,821 |
Amortization |  |  | 15,107 |  |  |  | 3,751 |
Stock-based compensation expense |  |  | 3,560,509 |  |  |  | 2,413,375 |
Professional fees |  |  | 966,815 |  |  |  | 574,598 |
Interest (income) expense, net |  |  | (3,193 | ) |  |  | 38,835 |
Equity in net income from equity method investees |  |  | (4,851 | ) |  |  | - |
Other income |  |  | (139,420 | ) |  |  | (1,086,422 | )
Segment net loss |  |  | (7,607,182 | ) |  |  | (4,648,709 | )
Reconciliation of net loss |  |  |  |  |  |  |  |
Adjustments and reconciling items |  |  | - |  |  |  | - |
Consolidated net loss |  | $ | (7,607,182 | ) |  | $ | (4,648,709 | )
(a) | Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.
(b) | Revenue concentrations are reflected in Note 9

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration